Recon: EU in talks to secure COVID-19 vaccines; NICE backs Astellas’ Xospata

• Three more biotechs tumble onto Wall Street today, raising $475M as the IPO party rocks on (Endpoints)
• CDC to recommend against retesting coronavirus patients before they end isolation (Politico)
• The Latest: 3M files lawsuits for price gouging of N95 masks (AP)
• Corbus Pharma is nearing the readout of a pivotal drug study. Here’s what you need to know (STAT)
• 'Meaningless' FDA Certificates Are Used To Tout Dubious Face Masks (NPR)
• Sens. Elizabeth Warren and Bernie Sanders slam Trump for giving Gilead ‘windfall’ deal for coronavirus drug (CNBC)

• EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines, sources say (Reuters)
• EU Leaders Meet In Hopes Of Closing Divisions Over COVID-19 Relief Package (NPR)
• Sanofi Considers US Biotech Targets Including Principia (Bloomberg)
• UK builds up Covid-19 medicines stockpile in case of second wave (Financial Times)
• NICE recommends Astellas’ Xospata for NHS use (PMLive)
• In Coronavirus Vaccine Race, China Strays From the Official Paths (NYTimes)
• Hong Kong Gives Nod to Asia’s Biggest Healthcare Listing in 2020 (Bloomberg) (Endpoints)
• Japan Might Tap Coronavirus Emergency Reserve for Vaccines (PharmaJapan)

• New Covid-19 study, despite flaws, adds to case against hydroxychloroquine (STAT)
• India Coronavirus Cases Surge Past One Million (NYTimes)
• Exclusive: White House Document Shows 18 States In Coronavirus “Red Zone” (Center for Public Integrity)
• Operation Warp Speed doesn’t have the transparency it needs (STAT)
• Hospitals’ recovery plans clash with new Covid infections (Politico)
• Who took down the CDC’s coronavirus data? The agency itself. (Politico)
• How HHS’s new hospital data reporting system will actually affect the U.S. Covid-19 response (STAT) (ProPublica)
• UK MHRA Relies On Remote Drug GMP Inspections As COVID-19 Pandemic Grounds Inspectors (Pink Sheet)
• CDC bans U.S. cruises through September, citing ‘ongoing’ coronavirus outbreaks on ships (CNBC)
• 3 Quest COVID-19 assays get FDA OK for at-home collection via telehealth (MedtechDive)
• BD sells 750K antigen tests to HHS as COVID-19 nursing home testing scales up (MedtechDive)
• Coronavirus (COVID-19) Update: Daily Roundup July 16, 2020 (FDA)

• Improving Clinical Trial Enrollment — In the Covid-19 Era and Beyond (NEJM)
• Startup Spotlight: Glympse Bio hopes its test will show whether drugs are actually working (STAT)
• As Amazon builds new health ventures, Haven struggles to gain ground (STAT)
• AstraZeneca's Brilinta looks for label boost with trial win, priority review in stroke patients (Fierce)
• AstraZeneca’s Farxiga scores another FDA fast-track designation (PMLive)
• Merck, Bayer get FDA priority review for heart failure drug (PMLive)
• In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan (Endpoints)
• Eli Lilly’s mirikizumab joins the club beating up on Cosentyx as another head-to-head study leaves Novartis’ drug in the dust (Endpoints) (Press)
• J&J-partnered MeiraGTx aims at Biogen with new eye gene therapy data (Endpoints)
• Pharma's TV ad spending level sets in June, with AbbVie, Sanofi and Regeneron leading the way (Fierce)
• A Jennifer Doudna-led team finds a new CRISPR enzyme in the giant viruses of a California mud bog (Endpoints)
• BMS gets the ball rolling on liso-cel in Europe; BeiGene files China NDA for in-house PARP drug (Endpoints)
• DoorDash partners with Walgreens to deliver over-the-counter drugs and other health products (CNBC)
• Tony Kingsley takes over the reins at Scholar Rock; Idorsia taps pharma vet Patricia Torr for new US ops (Endpoints)

• J&J drops planned 510(k) for Verb-Auris general surgery robot, targets 2022 clinical trial start (MedtechDive)
• FDA Gives Less Than 36 Hours’ Notice On Closure Of COVID-19 Hotline (MedtechInsight)
• UK Health Care At The Crossroads As Medtechs Watch For Bill, Brexit And NHS Change (MedtechInight)
• Ambu wins FDA clearance for single-use duodenoscope product (MedtechDive)
• XACT Robotics nets FDA clearance for second-generation needle surgery system (Fierce)
• Merck taps Novocure's cancer-fighting electric fields for new Keytruda combination study (Fierce)

• CVS Fined for Prescription Errors and Poor Staffing at Pharmacies (NYTimes)
• Democrats use inspector general report to renew calls for Medicare chief's ouster (Politico)
• How A Medicare Payment ‘Loophole’ Boosts Spending On Orencia, Cimza (Pink Sheet)
• 9th Circ. Skeptical Calif. Pay-For-Delay Law Poses Danger (Law360)
• Gilead Tries To Shake Antitrust Suit Over Expensive HIV Drugs (Law360)
• Pfizer, Mylan Push To Pare Down EpiPen Class Action (Law360)
• Covidien Asks 1st Circ. To Hand It Ex-Worker's Device Patents (Law360)
• 6th Circ. Again Refuses To Boot Judge From Opioid MDL (Law360)